Market revenue in 2023 | USD 7.8 million |
Market revenue in 2030 | USD 50.0 million |
Growth rate | 30.4% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Diagnostics |
Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 82.05% in 2023. Horizon Databook has segmented the Mexico peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico’s pharmaceutical industry is the second-largest in Latin America. Its growth is primarily due to the local presence of key market players, an increasing number of startups, and rising investments, which are collectively anticipated to fuel the market growth.
Furthermore, increasing medical tourism in Mexico due to the availability of cost-effective healthcare services is expected to make it a preferred destination for treatment. These factors are expected to boost the demand for peptide-based therapeutics in the country.
Mexico has a high rate of target diseases coupled with the growth of the country's biotechnology & biopharmaceutical industries, owing to the increasing number of startups and rising investments. These factors are expected to contribute to market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico peptide drug conjugates market , including forecasts for subscribers. This country databook contains high-level insights into Mexico peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account